hackint0sh/New-Dataset huggingface dataset:
The researchers will compare the changes with healthy controls and those without treatment-resistant schizophrenia. conditions: Treatment-resistant Schizophrenia conditions: Treatment-responsive Schizophrenia conditions: Healthy Controls studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This is a basic science study the purpose of which is to to explore the responsivity of glutamate in treatment-resistant schizophrenia to a given challenge (riluzole). primaryPurpose: BASIC_SCIENCE masking: NONE count: 288 type: ESTIMATED name: Riluzole measure: Change in glutamate levels (using magnetic resonance spectroscopy) pre- and post-riluzole administration measure: Correlation of glutamate (using magnetic resonance spectroscopy) with brain functional measures at baseline (using functional magnetic resonance imaging) measure: Longitudinal change in glutamate levels (using magnetic resonance spectroscopy) correlated with longitudinal change in brain functional measures (using functional magnetic resonance imaging) measure: Longitudinal change in glutamate levels (using magnetic resonance spectroscopy) correlated with changes in psychopathology sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute of Psychiatry, Psychology and Neuroscience status: RECRUITING city: London zip: SE5 8AB country: United Kingdom name: James Scott role: CONTACT phone: +44 207 848 0002 email: james.1.scott@kcl.ac.uk name: Guy Gitlin-Leigh role: CONTACT email: guy.1.gitlin-leigh@kcl.ac.uk name: Oliver D Howes role: PRINCIPAL_INVESTIGATOR lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06270095 id: C21-57 briefTitle: " Fume Events in Air Flights: Consequences on Cabin Air Quality and on Aircrews Health of a French Fleet of Aircraft" acronym: AVISAN overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-04 date: 2025-04 date: 2024-02-21 date: 2024-02-21 name: Institut National de la Santé Et de la Recherche Médicale, France class: OTHER_GOV name: Université Paris Cité name: National Agency for Sanitary Safety of the Food of the Environment and Labor briefSummary: The subject of the study focuses on commercial aircraft's cabins air quality, under conditions of both fume events and non-fume events. It also delves into the immediate and delayed repercussions of these events on the health of aviation crew members. The expological facet of this study is directed at the detection and quantification of organophosphorus compounds originating from engine oils. The epidemiological facet is geared towards the identification of potential neurological consequences. conditions: Neurologic Symptoms conditions: Neurologic Disorder studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1200 type: ESTIMATED name: Neurocognitive, neuromuscular and neurosensitive tests. measure: Neurocognitive self-assessment tests on digital tablet - CANTAB test battery: Paired Associates Learning measure: Neurocognitive self-assessment tests on digital tablet - CANTAB test battery: Rapid Visual Information Processing measure: Neurocognitive self-assessment tests on digital tablet - CANTAB test battery: One Touch Stockings of Cambridge measure: Neurosensitive test to explore superficial and deep sensitivity deficits in peripheral neuropathies measure: Neuromuscular test to evaluate muscle strength assessment measure: Symptoms experienced during the flight or within 72 hours after the flight, duration of symptoms, symptoms experienced previously outside the flight measure: Characteristics of plane and fume event and possible causes of fume event measure: Measurement of organophosphorus and carbon monoxide in cabin air using an air sampler and a piston syringe. sex: ALL minimumAge: 18 Years maximumAge: 67 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06270069 id: 2024-001 briefTitle: Responsiveness and Minimal Important Change of Two Measures of Pain Intensity in People With Low Back Pain overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-02-28 date: 2025-02-28 date: 2024-02-21 date: 2024-02-21 name: International Institute of Behavioral Medicines class: OTHER briefSummary: This is an observational study aimed at evaluating the responsiveness and minimal important change of two measures of pain intensity in people with low back pain. It consists of a battery of self-administered questionnaires which will be given to individuals with low back pain to complete before and after a rehabilitation treatment. Relationships among the different outcome measures will be also evaluated. conditions: Low Back Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED name: Excercise-based therapy measure: NRS measure: Gauge of pain measure: ODI measure: PCS measure: TSK measure: PSEQ measure: GPE sex: ALL minimumAge: 18 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06270056 id: 1058 briefTitle: Evaluation of Telemedicine Medical Abortion Service in Ecuador overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-02 date: 2025-02 date: 2024-02-21 date: 2024-02-21 name: Gynuity Health Projects class: OTHER briefSummary: This research seeks to demonstrate that a telemedicine model for the provision of legal abortion services in Ecuador is safe, feasible and acceptable to users requesting a medication abortion and who are less than 12 weeks pregnant. conditions: Pregnancy studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 100 type: ESTIMATED name: Misoprostol measure: Adverse events (safety) measure: Feasibility of telemedicine service measure: Acceptability of telemedicine service sex: FEMALE minimumAge: 15 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: El Comité de Derechos Sexuales y Reproductivos de Ecuador (CODESER) city: Ambato country: Ecuador name: Maria Fernanda Morales role: CONTACT phone: 593 998220369 email: mafer_moca@yahoo.es lat: -1.24908 lon: -78.61675 facility: Cemoplaf city: Quito country: Ecuador name: Gabriela Rivera role: CONTACT phone: 593 995512828 email: gabyrivera2398@hotmail.com lat: -0.22985 lon: -78.52495 facility: Federación Nacional de Obstetrices y Obstetras del Ecuador (FENOE) city: Quito country: Ecuador name: Paola Tito role: CONTACT phone: 593 22951737 email: paojaime@hotmail.es lat: -0.22985 lon: -78.52495 hasResults: False
nctId: NCT06270043 id: 809622 briefTitle: Focal Therapy for Localized Prostate Cancer overallStatus: RECRUITING date: 2024-02-01 date: 2034-02-01 date: 2034-02-01 date: 2024-02-21 date: 2024-02-26 name: University of California, San Diego class: OTHER briefSummary: This prospective registry and longitudinal study that is designed to carefully measure details of prostate cancer patients' outcomes with focal therapy. The goal of which is to improve patient care. conditions: Prostate Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: Focal Therapy measure: Oncological Response measure: Erectile Dysfunction measure: Incontinence measure: Prostate cancer recurrence. Patients will be monitored with a Prostate Specific Antigen (PSA) every 6 months until 10 years from the intervention. Patients with a rising PSA will receive a prostate biopsy to determine if they have a recurrence. sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of California, San Diego status: RECRUITING city: La Jolla state: California zip: 92121 country: United States name: Juan Javier-DesLoges, MD role: CONTACT phone: 858-657-8786 email: jjavierdesloges@health.ucsd.edu lat: 32.84727 lon: -117.2742 hasResults: False
nctId: NCT06270030 id: JX07002 id: CTR20240460 type: OTHER domain: China Center for Drug Evaluation (CDE), NMPA briefTitle: Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia overallStatus: COMPLETED date: 2024-03-04 date: 2024-04-10 date: 2024-04-10 date: 2024-02-21 date: 2024-04-23 name: Ji Xing Pharmaceuticals (Shanghai) Co., Ltd. class: INDUSTRY name: LENZ Therapeutics, Inc briefSummary: Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Chinese Healthy Adult Subjects with Presbyopia conditions: Presbyopia studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 21 type: ACTUAL name: LNZ101 (Aceclidine /Brimonidine) ophthalmic solution name: LNZ100 (Aceclidine) ophthalmic solution name: Placebo (Vehicle) ophthalmic solution measure: Cmax measure: Tmax measure: AUC0-t measure: AUC0-∞ measure: T1/2 measure: Safety: adverse event reporting sex: ALL minimumAge: 45 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai General Hospital city: Shanghai state: Shanghai zip: 200080 country: China lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06270017 id: 282242 briefTitle: Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars acronym: ZEBRA-COLON overallStatus: RECRUITING date: 2022-01-10 date: 2025-12-31 date: 2028-12-31 date: 2024-02-21 date: 2024-02-21 name: University Hospital, Linkoeping class: OTHER briefSummary: In order to improve and individualize cancer treatment personalized treatments developed much further. Colon cancer is treated with surgery and thereafter adjuvant oncological treatment. The selection of chemotherapy is today mainly done according to best guess. Today only a small fraction of oncological treatment may be known to be effective in a person before treatment start, most often it is trial and error. A fast reliable system for looking at response to different treatments in each unique patient is much needed and would, if successful, completely change the way we give oncological treatment today. This system would also be possible to use to evaluate new treatments and if successful, implement in the clinical setting. In this project we will implant a part of the patient's tumour tissue into a zebrafish embryo and evaluate tumour growth and frequency of metastatic disease as well as response to given oncological treatment.
2.3 Study design: This protocol describes a series of prospective studies in different cohorts of patients with colon cancer to investigate the applicability of zebrafish embryo models. The common denominator of the sub-studies is prospective collection of tumor tissue implanted in zebrafish embryos in order to evaluate if the model is robust enough for growing colon cancer tissue and evaluate growth pattern and response to chemotherapy. This study protocol is designed according to and in adherence with the SPIRIT guidelines.
2.4 Intervention: In all sub-studies the intervention is inoculation of tumor cells in zebrafish embryos followed by observation of tumor behavior and testing of treatments. conditions: Colon Cancer studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Evaluation of patients derived colon cancer tumour cell growth in zebra fish embryos and response evaluation of combinations of chemotherpy primaryPurpose: DIAGNOSTIC masking: NONE count: 300 type: ESTIMATED name: Chemotherapy drug measure: Tumour growth measure: response evaluation sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Per Sandström status: RECRUITING city: Linköping state: Ostergotland zip: 58185 country: Sweden name: Per Sandström, Prof role: CONTACT phone: +46734058581 email: per.sandstrom@liu.se name: Bergthor Bjornsson, MD PhD role: CONTACT phone: +46101033666 email: bergthor.bjornsson@liu.se lat: 58.41086 lon: 15.62157 hasResults: False
nctId: NCT06270004 id: nonsurgical periodontal briefTitle: Effect of Nonsurgical Periodontal Therapy on Salivary Biomarkers Related to Bone Turnover in Smoker and Nonsmoker Periodontitis Patients overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-11-01 date: 2024-12-01 date: 2024-02-21 date: 2024-02-21 name: University of Baghdad class: OTHER briefSummary: 1. To assess the alteration in the level of salivary osteopontin (OPN), osteonectin(ON) and histatin-1 following NSPT in smoker and nonsmoker unstable periodontitis patients at different time intervals(one month and three months) .
2. To evaluate the response of clinical periodontal parameters ( plaque index ,bleeding on probing ,probing pocket depth ,clinical attachment loss)following NSPT in smoker and nonsmoker unstable periodontitis patients at different time intervals (one month and three months) conditions: Non Surgical Periodontal Therapy studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: smoker and non smoker patients with unstable periodontitis primaryPurpose: OTHER masking: NONE count: 30 type: ESTIMATED name: nonsurgical periodontal therapy measure: Effect of nonsurgical periodontal therapy(NSPT) on salivary biomarkers related to bone turnover in smoker and nonsmoker periodontitis patients. measure: Effect of nonsurgical periodontal therapy(NSPT) on salivary biomarkers related to bone turnover in smoker and nonsmoker periodontitis patients. measure: Effect of nonsurgical periodontal therapy(NSPT) on salivary biomarkers related to bone turnover in smoker and nonsmoker periodontitis patients sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06269991 id: SBA23/083 briefTitle: Fascial Anthropometry in Archery Athletes overallStatus: NOT_YET_RECRUITING date: 2024-02-15 date: 2024-09-06 date: 2025-09-06 date: 2024-02-21 date: 2024-02-21 name: Hacettepe University class: OTHER briefSummary: In archery, the body morphological and anthropometric characteristics of the prominent athletes change. It is important to examine facial anthropometry, especially since the athlete's equipment touches the facial area, and there are no studies on this subject. The aim of this study is to determine the relationship between facial anthropometric measurements and anthropometry-related parameters and sports performance in archery athletes. conditions: Sports Physical Therapy studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 60 type: ESTIMATED measure: evaluation of cervical region biomechanic measure: fat tissue distribution measure: head circumference measure: extremity circumference measure: extremity lengt measurement measure: knee and elbow diameter measure: nose width measure: chin width measure: face width measure: head width measure: nose protrusion measure: nose lenght measure: head lenght measure: face lenght measure: lip lenght measure: Assessment of Perıpheral Muscle Strength measure: postural analysis measure: Evaluation of shooting performance measure: The seated medicine ball throw (SMBT) measure: Closed Kinetic Chain Upper Extremity Stability Test measure: Upper Quarter Y Balance Test sex: ALL minimumAge: 9 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Hacettepe University city: Ankara zip: 06100 country: Turkey name: Aynur Demirel role: CONTACT phone: +905545295057 phoneExt: 178 email: aynur.demirel@hacettepe.edu.tr name: Nisanur Kutay role: CONTACT phone: +905515549957 email: kutaynisanur@gmail.com name: Nisanur Kutay role: SUB_INVESTIGATOR lat: 39.91987 lon: 32.85427 hasResults: False
nctId: NCT06269978 id: OSU-23195 id: NCI-2023-10497 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: R21CA282536 type: NIH link: https://reporter.nih.gov/quickSearch/R21CA282536 briefTitle: Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer overallStatus: RECRUITING date: 2024-04-30 date: 2025-12-31 date: 2025-12-31 date: 2024-02-21 date: 2024-03-27 name: Arjun Mittra class: OTHER name: National Cancer Institute (NCI) briefSummary: This phase I trial tests the safety, side effects, and best dose of intraperitoneal oxaliplatin and fluorouracil in treating patients with colorectal cancer that has spread to the peritoneal cavity (peritoneal metastasis). Oxaliplatin is in a class of medications called platinum-containing antineoplastic agents. It damages the cell's DNA and may kill cancer cells. Fluorouracil stops cells from making DNA and it may kill cancer cells. Both oxaliplatin and fluorouracil are approved by the Food and Drug Administration to treat patients with colorectal cancer, however administration of these drugs directly into the area between the muscles and organs in the abdomen (intraperitoneal) for the treatment of peritoneal metastases is experimental. Giving oxaliplatin and fluorouracil directly into the peritoneal space may be a safe and effective way of treating patients with peritoneal metastases from colorectal cancer. conditions: Metastatic Colorectal Carcinoma conditions: Metastatic Malignant Neoplasm in the Peritoneum conditions: Stage IV Colorectal Cancer AJCC v8 studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: Biopsy name: Biospecimen Collection name: Computed Tomography name: Diagnostic Laparoscopy name: Fluorouracil name: Magnetic Resonance Imaging name: Oxaliplatin name: Surgical Procedure measure: Maximum tolerated dose (MTD) measure: Incidence of adverse events measure: Area under the curve measure: Clearance measure: Volume of distribution measure: Half-life measure: Tumor-cell intrinsic effects in response to IP 5FU+oxaliplatin measure: Modulation of the tumor microenvironment in response to IP 5FU+oxaliplatin measure: Changes in the makeup of circulating immune cells in response to IP 5FU+oxaliplatin measure: Rate of conversion from unresectable to resectable measure: Overall response rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Ohio State University Comprehensive Cancer Center status: RECRUITING city: Columbus state: Ohio zip: 43210 country: United States name: Arjun Mittra, MD role: CONTACT phone: 614-293-6529 name: Arjun Mittra, MD role: PRINCIPAL_INVESTIGATOR lat: 39.96118 lon: -82.99879 hasResults: False
nctId: NCT06269965 id: 2023-A02181-44 briefTitle: Assessment of Collagen Membrane Interest in Distal Cuff Lesions Repair acronym: REGENECUFF overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2027-04-15 date: 2027-04-15 date: 2024-02-21 date: 2024-02-29 name: GCS Ramsay Santé pour l'Enseignement et la Recherche class: OTHER briefSummary: Rotator cuff refers to a set of 4 shoulder tendons. These tendons are the sub-scapularis, supra-spinatus, infra-spinatus and teres minor. Rotator cuff tear corresponds to total or partial tendon disinsertion at the greater tuberosity level or a few centimeters in upstream.
Rotator cuff surgery is an increasingly popular procedure practiced in France. In limited cuff lesions (distal or intermediates) and in absence of contraindication, absence of tendons' healing is around 10 to 20%. Sofcot estimates that 90% of caps' heals remain healed 10 years after surgery in distal lesions. However, even in case of a healed cuff, if tendon quality is not good, function will be impaired.
In this context, this study is based on hypothesis that adding Regeneten® during rotator cuff repair could be beneficial on tendon healing rate but also on tendon quality healing. conditions: Cuff Rotator Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 204 type: ESTIMATED name: Regeneten® adding measure: Rotator cuff healing quality sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06269952 id: MVarmafalk briefTitle: Intimate Partner Violence Among People Who Inject Drugs - Prevalence, Risk Factors and Experiences overallStatus: RECRUITING date: 2023-10-05 date: 2025-03 date: 2028-12 date: 2024-02-21 date: 2024-02-21 name: Region Stockholm class: OTHER_GOV briefSummary: There are around 15,6 million people who inject drugs (PWID) worldwide, of which around 3,5 million are women who inject drugs (WWID) (1). In Sweden, estimates suggest 8000-21000 PWID (2). PWID are exposed to substantial health risks that are directly linked to injection drug use, such as blood borne viruses (hepatitis and HIV), overdoses and skin and tissue infections. Additionally psychiatric disorders are common and PWID's general health is often neglected (3,4,5).
In Sweden, harm reduction units such as needle and syringe programs (NSP) have scaled-up in recent years. In Stockholm the first NSP opened in 2013 and the second in 2018. In 2022, 4600 individuals were enrolled in the program since it opened, of which approximately 25% were women. Around 2000 were active participants, defined as having visited the program at least once during the last 12 months. In 2021 54% of the participants stated amphetamine as the last drug injected, 31% heroin, 4% buprenorphine and 11% other drugs. Most participants were between 30-49 years of age. In addition to distribution of sterile needles and injection paraphernalia, the NSP staff (nurses, doctors, midwifes, counselors) provides services such as testing for blood borne viruses, vaccinations, wound care, take-home naloxone, reproductive health services, counselling, support in contact with social service and referrals for substance use disorder treatment and hepatitis C/HIV treatment.
Gender-based violence (GBV) is a global health issue and WHO estimates that one in three women globally have been exposed to some sort of partner violence during their lifespan (7). Intimate partner violence (IPV) is defined as violent behavior between two people who have a close relationship, such as partners, ex-partners, siblings, relatives, friends and alike. In Sweden around 14% of women and 5% of men are exposed to physical violence in an intimate partner relationship during their lifespan however 20-25% of women and around 17% of men are exposed to psychological violence during their lifespan (8; 9). The prevalence of IPV among PWID is estimated to be significantly higher than in the general population (10). A study from USA found the risk of IPV to be three times higher and the prevalence estimated between 35-57% (7). In international studies, IPV exposure is found to be a significant risk factor for needle sharing among WWID (11, 12). There are other well-known consequences of IPV including impact on sexual and reproductive health rights, physical and psychological wellbeing, increased risk of contracting HIV and hepatitis C (13; 14). IPV exposure disproportionately affects WWID worldwide, however studies in Sweden on IPV exposure in the PWID population is scarce. To date there are studies that address this among women with substance use disorders but none with an exclusive focus on PWID or WWID. In clinical research of women diagnosed with substance use disorders (SUD) with psychiatric comorbidities and social challenges, one study indicates that the majority (91%, n=79) of women had been exposed to some form of IPV (15). Another study of women with SUD (n=52), 50% reported exposure of serious violence and the majority (96%) reported exposure to psychological violence (10). There are different types of IPV; psychological, physical, sexual, financial, latent, digital, neglect, honor related, aftermath of IPV (16). Our research team has previously carried out a qualitative interview study among WWID at the Stockholm NSP in 2019 to investigate reasons and barriers for participation among women (17). The interviews illustrated that IPV is common. In the proposed studies, for this doctoral thesis, we have chosen to focus on physical, sexual, psychological and financial violence among PWID motivated by findings in our previous research.